Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503-513.
Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3–encoded protein:
a new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327-337.
Deng W-W, Mao L, Yu G-T, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in
head and neck squamous cell carcinoma. Oncoimmunology. 2016;5(11):e1239005.
doi:10.1080/2162402X.2016.1239005.
Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II
interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol.
1995;25(9):2718-2721.
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali AA. Lymphocyte activation gene-3 (CD223)
regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol.
2004;172(9):5450-5455.
Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory
receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37.
Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during
recurrence of melanoma. J Immunol. 2013;190(9):4899-4909.
Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in
murine self- and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383-3392.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are
negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A.
2010;107(17):7875-7880.
Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4+CD25highFoxp3+ regulatory T
cells that are expanded at tumor sites. J Immunol. 2010;184(11):6545-6551.
Yang Z-Z, Kim HJ, Villasboas JC, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells
and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8(37):61425-61439.
Huang R-Y, Francois A, McGray AJR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and
CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology.
2017;6(1):e1249561. doi:10.1080/2162402X.2016.1249561.
Wierz M, Pierson S, Guyonnet L, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in
a murine model of chronic lymphocytic leukemia. Blood. 2018. doi:10.1182/blood-2017-06-792267.
Huang R-Y, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules
collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Oncotarget. 2015;6(29):27359-27377. 15. Lichtenegger FS, Rothe M, Schnorfeil FM, et al. Targeting LAG-3 and
PD-1 to enhance T cell activation by antigen-presenting cells. Front Imunol. 2018;9:385.
doi:10.3389/fimmu.2018.00385.